Welcome to our dedicated page for Indaptus Therapeutics news (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics stock.
Indaptus Therapeutics develops clinical-stage immunotherapies for cancer and viral infections using its Decoy bacterial platform. The company’s lead candidate, Decoy20, is based on attenuated and killed, non-pathogenic Gram-negative bacteria designed to activate innate and adaptive immune responses, with a focus on solid tumors.
Recurring news for Indaptus covers clinical updates from the INDP-D101 program, including Decoy20 evaluation as monotherapy and in combination with the PD-1 inhibitor tislelizumab. Company updates also include preclinical research on immune-cell activation, quarterly financial results, private placements, convertible notes and warrants, at-the-market financing, reverse stock split actions, Nasdaq compliance matters, and scientific or investor conference presentations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.